The University of Wisconsin Carbone Cancer Center (UWCCC) Protocol Review and Monitoring System (PRMS) operates via one main committee, the Protocol Review and Monitoring Committee (PRMC), which functions as the Scientific Review Committee for alt cancer-related research protocols. The PRMC is charged with the scientific and resource review of all new and ongoing clinical and translational research protocols. In addition, the PRMC reviews all cancer-related clinical and translational research for compliance with the UW-Madison Conflict of Interest policies and assures an appropriate Data and Safety and Monitoring Plan is included in each proposal. The PRMC accomplishes this via the following responsibilities; ? Review of all new clinical and translational trials for scientific merit, priorities and resource allocation ? Prioritization of new clinical and translational trials relative to the clinical Disease Oriented Working Groups (DOWG)/Clinical Research Groups (CRG) ? Prioritization of research relative to the scope of UWCCC ? Review of all ongoing clinical and translational trials for scientific progress ? Closing studies for insufficient progress or due to prioritization changes Through established procedures the PRMC is the oversight mechanism through which all UW-Madison cancer-related clinical and translational research must flow, thus assuring that all research conducted at UWCCC is of the highest scientific merit and that UWCCC resources are used efficiently. The PRMS is supervised by the Associate Director for Clinical Research. The PRMC reports to UWCCC Clinical Research Committee, and is chaired by Dan Mulkerin, M.D., Associate Professor of Medicine, and co-chaired by Menggang Yu, Ph.D., Assistant Professor of Biostatistics and Medical Informatics. Dr. Mulkerin has over 15 years of clinical research performance and monitoring. Dr. Yu served as the biostatistics and clinical data management director for the Hoosier Oncology Group for four years prior to joining the University of Wisconsin faculty in January 2012.

Public Health Relevance

The UWCCC Protocol Review and Monitoring System (PRMS) operates via one main committee, the Protocol Review and Monitoring Committee (PRMC), which functions as the Scientific Review Committee for all cancer-related research protocols. The PRMC is charged with the scientific and resource review of all new and ongoing clinical and translational research protocols. In addition, the PRMC reviews all cancer related clinical and translational research for compliance with the UW-Madison Conflict of Interest policies and assures an appropriate Data and Safety and Monitoring Plan is included in each proposal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762776
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$145,814
Indirect Cost
$59,442
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Goel, Shreya; Ferreira, Carolina A; Chen, Feng et al. (2018) Activatable Hybrid Nanotheranostics for Tetramodal Imaging and Synergistic Photothermal/Photodynamic Therapy. Adv Mater 30:
Wei, Weijun; Ehlerding, Emily B; Lan, Xiaoli et al. (2018) PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging 45:132-150
Yu, Bo; Wei, Hao; He, Qianjun et al. (2018) Efficient Uptake of 177 Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy. Angew Chem Int Ed Engl 57:218-222
Ehlerding, Emily B; Lacognata, Saige; Jiang, Dawei et al. (2018) Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody. Eur J Nucl Med Mol Imaging 45:123-131
Shea, Michael P; O'Leary, Kathleen A; Wegner, Kyle A et al. (2018) High collagen density augments mTOR-dependent cancer stem cells in ER?+ mammary carcinomas, and increases mTOR-independent lung metastases. Cancer Lett 433:1-9
Conklin, Matthew W; Gangnon, Ronald E; Sprague, Brian L et al. (2018) Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma In Situ. Cancer Epidemiol Biomarkers Prev 27:138-145
Ko, Huaising C; Kimple, Randall J (2018) The Resident Individual Development Plan as a Guide for Radiation Oncology Mentorship. Int J Radiat Oncol Biol Phys 101:786-788
McDermott, Andrew J; Tumey, Tyler A; Huang, Mingwei et al. (2018) Inhaled Cryptococcus neoformans elicits allergic airway inflammation independent of Nuclear Factor Kappa B signalling in lung epithelial cells. Immunology 153:513-522
You, Xiaona; Kong, Guangyao; Ranheim, Erik A et al. (2018) Unique dependence on Sos1 in Kras G12D -induced leukemogenesis. Blood 132:2575-2579
Ferreira, Carolina A; Hernandez, Reinier; Yang, Yunan et al. (2018) ImmunoPET of CD146 in a Murine Hindlimb Ischemia Model. Mol Pharm 15:3434-3441

Showing the most recent 10 out of 1528 publications